$QLGN – Qualigen Therapeutics, Inc., promotional campaign starting Oct 11, 2021 @ 6:13 AM CST

on October 11, 2021 Stock Promotion Tracking and Tags: , , , , , , , , , with 0 comments

Summary

Start time:
6:13 AM
Start date:
October 11, 2021
Symbol:
QLGN
Company:
Qualigen Therapeutics, Inc.
Stock promoter:
"OTC Stock Review"
Stock promoter rank:
19 out of 25
Promoter score:
7.6
Campaign ID:
36723

Qualigen Therapeutics, Inc.

Market capitalization:
$45,267,903
(as of August 31, 2021)
Outstanding shares:
28,833,059
(as of May 7, 2021)

Stock Promoter Performance

The following charts displays the first day results for campaigns by "OTC Stock Review". Results are taken from a total of 15 stock promotions by this stock promoter that have been tracked by OTC Dynamics.
40% closed down

36% closed up

22% had no net effect

Last 1 Stock Promotions By "OTC Stock Review"

Symbol Company Start Date Close Change
QSAM QSAM Biosciences Inc. August 18, 2021 0.410 11%

QLGN Promotional Newsletter

The following is a newsletter released by "OTC Stock Review" promoting Qualigen Therapeutics, Inc.

Caution

The following newsletter has not been verified for accuracy or completeness.

Sh

office 404 856-9157

toll-free 866 692-6847

OTC Stock Review Award Winning Small Cap Stock Picks Since 2004

Qualigen Therapeutics Plans to Combat Cancer

Qualigen Therapeutics NASDAQ QLGN is at $1.23 and trading very quietly, which is usually a great time to buy.

Zack's Research has a recent long-term price target of $9.00.

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation. Qualigens aptamer platform, of which QN-247 is the lead candidate, inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells, thus influencing their proliferation, survival and metastasis.

QN-247 has shown promise in pre-clinical studies for the treatment of acute myeloid leukemia AML. Qualigens RAS-F platform is a family of RAS oncogene protein-protein interaction inhibitor small molecules that is believed to disrupt pathways for cancer genes that cause tumor formation. Such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers.

The RAS pathway has generated considerable interest due to recent breakthrough developments in the field and the first clinical approval earlier this year for a K-RAS directed drug.

In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems for the management of prostate cancer and other diseases and health conditions.

Qualigens management has significant experience in drug and medical device development, manufacturing, marketing and distribution.

Qualigen Overview

Products and Pipeline Includes novel platform technologies to treat multiple cancer types and viral diseases

Resources $15 million in cash providing runway well into 2022 to hit significant value-driving inflection points starting this year

Team Experienced and growing leadership team with a proven track record in development and commercialization

Partnerships Leveraging prominent investigators at major research institutions to cost-efficiently advance development

Value Extensive global IP portfolio over 100 owned or in-licensed, issued or pending patents and applications

Since inception, sales of FastPack products have exceeded $100 million.

To learn more about Qualigen, visit its website here.

Qualigen Therapeutics, Inc.

Price $1.23

NASDAQ Symbol QLGN

Market Cap $35.7 million

Shares Outstanding 28.83 million

Sector Health Care

Industry Biotechnology

52 Week HighLow $7.34$1.16

2042 Corte Del Nogal

Carlsbad, CA 92011

Phone

WebsiteWebsite

Qualigen has been in business 25 years and has sold its FastPack products in the United States and overseas for almost 20 years.

OTC Stock Review is not registered as an Investment Advisor or a BrokerDealer. The information in this newsletter is not an offer to buy or sell securities of the companies profiled. Information is for informative purposes, not intended as advice for investment and is subject to change without notice. OTC Stock Review is been compensated seven thousand five hundred dollars a month and twelve thousand five hundred shares of common stock restricted under Rule 144 to perform investor relations services for Qualigen. Officers and directors of OTC Stock Review may hold a long equity position in QLGN and may from time to time trade in these securities for their own accounts. Information on each company is from public releases and can not be guaranteed by OTC Stock Review. Companies profiled herein may carry a high investment risk readers should carefully review profiled companies thoroughly with their investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled Companies and reflects the opinion of the author. Readers should obtain copies of the profiled Companys periodic reports filed with United States Securities and Exchange Commission, generally available at or .

If you no longer wish to receive these emails, please reply to this message with Unsubscribe in the subject line or simply click on the following link

to forward this email to a friend

OTC Stock Review
235 Peachtree St. NE
Suite 400
Atlanta, Georgia 30303
US

the marketing policy.

Get Every Penny Stock Alert!

OTC Dynamics tracks all penny stock promotions. Become a member today and never miss another penny stock promotion!

Sign up today!

Note

OTC Dynamics is not affiliated with the company being promoted or the associated stock promoter.

The information on this page is not a recommendation to buy or sell securities.